Valproic Acid Injection |
Depacon; Valproate Sodium |
Clinical Trial: A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Solid Tumors
This study is currently recruiting patients.
Verified by Merck August 2005
|
Purpose
The primary purpose of this trial is to determine the maximum tolerated dose (MTD), or the maximum acceptable dose (MAD) and evaluate the dose limiting toxicity (DLT) of oral suberoylanilide hydroxamic acid in patients with solid tumors.
| Condition | Intervention | Phase |
|---|---|---|
| Tumors | Drug: MK0683, Suberoylanilide hydroxamic acid (SAHA) | Phase I |
MedlinePlus related topics: Cancer; Cancer Alternative Therapies
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Eligibility
Ages Eligible for Study: 20 Years - 75 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Patients with histologically or cytologically diagnosed solid tumor; no standard therapy available or patient has failed to respond to standard therapy
Exclusion Criteria:
- Patients with history of immunotherapy, radiotherapy, surgery, or chemotherapy during the previous 4 weeks; previous treatment is 5 or more chemotherapeutic regimens.
- Any uncontrolled concomitant illness
- Are pregnant or breast-feeding
- Serious drug or food allergy
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00127127
Call For Information +81-3-5203-8218
Japan, Chuoku
Call For Site Information, Tokyo, Chuoku, 103-8416, Japan; Recruiting
Study chairs or principal investigators
Medical Monitor, Study Director, Merck
More Information
Study ID Numbers: 2005_040
Last Updated: August 19, 2005
Record first received: August 3, 2005
ClinicalTrials.gov Identifier: NCT00127127
Health Authority: Japan: Ministry of Health, Labor and Welfare
ClinicalTrials.gov processed this record on 2005-08-23
Last Updated: August 19, 2005
Record first received: August 3, 2005
ClinicalTrials.gov Identifier: NCT00127127
Health Authority: Japan: Ministry of Health, Labor and Welfare
ClinicalTrials.gov processed this record on 2005-08-23
Resources
- Depacon (Drug Digest)
- Valproate Sodium (Drug Digest)

Not Signed In -


